NDA 050514 · Harrow Eye
Natacyn
Natamycin · Ophthalmic · Polyene Antimicrobial
Priority reviewLast checked: Nov 19, 2026Latest source record: Nov 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1978
Oct 30, 1978
Approved uses
1
Original approval plus efficacy supplements
Registered trials
14
10 Phase 3, 1 recruiting
FAERS reports
410
307 serious, 96 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 5, 2025.
INDICATIONS AND USAGE: NATACYN ® (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 30, 1978 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
- NATACYN · NATAMYCIN 5% · SUSPENSION, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Natamycin" as an intervention, any sponsor and status, largest first.
- RB-PDT for Fusarium Keratitis: The LUMIERE StudyPivotal-lookingNot yet recruiting
Stanford UniversityAcademic, hospital or other
NCT07743489 · 434 participants (planned) · Start Jan 2027 · Primary completion Apr 2029
Drug: Rose Bengal Photodynamic Therapy; Sham RB-PDT · For: Fusarium Keratitis
Sites: Palo Alto, California; Miami, Florida; São Paulo, Brazil · 4 sites in all
- Rose Bengal Electromagnetic Activation With Green Light for Infection ReductionPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT05110001 · 330 participants · Start Aug 3, 2022 · Primary completion Dec 14, 2024
Drug: Moxifloxacin Ophthalmic; Chlorhexidine Gluconate and 2 more · For: Acanthamoeba Keratitis; Fungal Keratitis
Sites: São Paulo, Brazil; Madurai, India
- Mycotic Ulcer Treatment Trial IPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT00996736 · 323 participants · Start Apr 2010 · Primary completion Jul 2012
Drug: Natamycin; Voriconazole · For: Corneal Ulcer; Eye Infections, Fungal
Sites: San Francisco, California; Madurai, India; Pondicherry, India
- The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs PlaceboPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT00997035 · 240 participants · Start May 2010 · Primary completion Jan 2016
Drug: Voriconazole; Placebo · For: Corneal Ulcer; Eye Infections, Fungal
Sites: San Francisco, California; Coimbatore, India; Madurai, India · 7 sites in all
- Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal CandidiasisPivotal-lookingCompleted
Avva Rus, JSCIndustry
NCT06411314 · 218 participants · Start Dec 29, 2022 · Primary completion Jul 26, 2023
Drug: Lactulose 300 mg vaginal suppositories; Pimafucin® (natamycin) 100 mg vaginal suppositories · For: Vulvovaginal Candidiasis, Genital
Sites: Moscow, Russia
- Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine APivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06658002 · 150 participants (planned) · Start Sep 1, 2025 · Primary completion Sep 1, 2027
Drug: Cyclosporine A · For: Fungal Keratitis; Corneal Ulcer
Sites: San Francisco, California; Pondicherry, India
- Cross-linking for Corneal Ulcers Treatment TrialPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT02570321 · 147 participants · Start Nov 2015 · Primary completion Jun 18, 2018
Drug: Anti Fungal Drug · For: Corneal Ulcer; Infectious Keratitis; Bacterial Ulcer and 1 more
Sites: San Francisco, California; Madurai, India
- Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal UlcerPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT00557362 · 120 participants · Start Nov 2007 · Primary completion Aug 2008
Drug: Natamycin 5%; Voriconazole · For: Fungal Keratitis
Sites: Madurai, India; Pondicherry, India
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective117
- condition aggravated100
- off label use81
- somnolence64
- abdominal distension62
- abdominal pain59
- vomiting59
- appendicitis58
- appendicolith58
- ascites58
- hyponatraemia58
- nausea58
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2010 | 6 |
| 2012 | 6 |
| 2013 | 7 |
| 2014 | 2 |
| 2015 | 10 |
| 2016 | 13 |
| 2017 | 15 |
| 2018 | 18 |
| 2019 | 21 |
| 2020 | 23 |
| 2021 | 47 |
| 2022 | 49 |
| 2023 | 67 |
| 2024 | 54 |
| 2025 | 43 |
| 2026 | 28 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Natacyn (Natamycin)
2024 spending
$970K
Beneficiaries
788
1,282 claims
Per beneficiary
$1,231
$49.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $74,340 |
| 2022 | $647,733 |
| 2023 | $766,662 |
| 2024 | $969,715 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Natamycin versus voriconazole for fungal keratitis.
Retamal J, Ordenes-Cavieres G, Grau-Diez A · Medwave 2018 · Comparative Study, Meta-Analysis
- Medical interventions for fungal keratitis.
FlorCruz NV, Evans JR · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Medical interventions for fungal keratitis.
FlorCruz NV, Peczon IV, Evans JR · Cochrane Database Syst Rev 2012 · Research Support, Non-U.S. Gov't, Systematic Review
- Predictors of vision-related quality of life in patients treated for filamentous fungal keratitis.
Prajna NV, Radhakrishnan N, Lalitha P, et al. · Ocul Surf 2025 · Randomized Controlled Trial, Multicenter Study
- Medical interventions for fungal keratitis.
Florcruz NV, Peczon I · Cochrane Database Syst Rev 2008 · Meta-Analysis, Systematic Review
- Fusarium Keratitis: A Systematic Review (1969 to 2023).
Cintra MEC, da Silva Dantas M, Al-Hatmi AMS, et al. · Mycopathologia 2024 · Systematic Review
Sponsor: Harrow Eye
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.